Alzheimer's disease
Also known as: Alzheimer disease, Alzheimer’s disease
synthesized from dimensionsAlzheimer's disease is a progressive neurodegenerative disorder characterized by the gradual decline of cognitive function, memory loss, and the destruction of nerve cells. It is fundamentally defined by the accumulation of pathological markers, specifically amyloid plaques and tau protein tangles, which disrupt neuronal communication and lead to widespread brain atrophy.
A central component of the disease's pathology is chronic, low-level inflammation within the central nervous system. The immune system often overreacts to the presence of plaques and tangles, triggering the release of damaging cytokines that exacerbate neuronal damage (Cedars-Sinai). Microglia, the brain's resident immune cells, become activated in response to these inflammatory proteins, further contributing to the neurodegenerative environment (Cedars-Sinai). This chronic inflammatory state is strongly linked to cognitive decline and dementia (National Library of Medicine).
Beyond inflammation, the etiology of Alzheimer's is multifaceted, with research exploring various contributing mechanisms. The oxidative stress hypothesis suggests that an imbalance between free radicals and the brain's antioxidant defenses plays a critical role in disease progression (Markesbery, 1997; Teixeira et al., 2019). Additionally, some researchers investigate the potential for an infectious etiology, proposing that external pathogens may trigger or accelerate the disease process (Sochocka, Zwolińska, and Leszek, 2017).
Therapeutic research is currently diverse, focusing on both pharmaceutical and natural interventions. Emerging strategies include the use of plant-derived cholinesterase inhibitors (ALNasser et al., Brain Sciences 2025), natural alkaloids (Vrabec et al., 2023), and compounds targeting GSK-3β (Wang et al., Frontiers in Pharmacology 2025). Other studies are exploring the neuroprotective potential of substances like ginsenoside RK1 (She et al., Phytomedicine 2024) and curcumin (Turer and Sanlier, 2025), as well as the potential role of psychedelics in neuro-regeneration (Garcia-Romeu et al., 2021; Steinberg et al., 2023).
Management and risk mitigation strategies emphasize lifestyle and preventative health measures. Physical activity is widely recognized as a protective factor against cognitive decline (Mayo Clinic Proceedings, 2016), and evidence suggests that annual flu vaccinations may reduce the risk of developing the disease (Cedars-Sinai). Conversely, clinical observations indicate that heavy use of non-steroidal anti-inflammatory drugs (NSAIDs) may paradoxically accelerate the progression of the disease in some contexts (Cedars-Sinai), highlighting the complexity of the inflammatory response in Alzheimer's pathology.